All products are for laboratory research use only. Not for human consumption.
Tissue Repair
The Sovereign Recovery Protocol
RM 500
Experience complete cellular restoration. This 20mg master blend unites structural repair with fluid mobility, resetting your body from the inside out.
For research use only. Not for human or veterinary consumption. This product is not a medicine and is not intended to diagnose, treat, cure or prevent any disease.
Overview
BPC-157 and Thymosin Beta-4 work through completely non-competing pathways: VEGFR2 angiogenesis brings blood supply; G-actin sequestering migrates repair cells to the site. Combined in equal 10mg+10mg proportions, both compounds maintain their full individual dose effect.
Mechanism of action
Angiogenesis and growth hormone receptor upregulation
Cytoskeletal regulation enabling cell migration to injury sites
Non-competing pathways — full dose effect from each compound
Key finding BPC-157 upregulates growth hormone receptors 7x at day 3, while TB-500 increases keratinocyte migration 200% vs control — two mechanisms that directly amplify each other when combined.
Key research findings
Growth hormone receptor upregulation on Day 3 in tendon healing models with BPC-157
Seiwerth S et al. J Physiol Pharmacol, 2018Faster re-epithelialization versus control in Phase 1 wound healing trial with TB-500
Malinda KM et al. J Invest Dermatol, 1999Increase in keratinocyte migration versus control group in TB-500 wound healing studies
Goldstein AL et al. Expert Opin Biol Ther, 2012No lethal dose found for either BPC-157 or TB-500 in standard toxicology studies
Sikiric P et al. Curr Pharm Des, 2018Research areas
VEGFR2 angiogenesis combined with G-actin cell migration for tendon, muscle, and bone repair.
ILK/Akt pathway supports cardiomyocyte survival alongside BPC-157 anti-inflammatory action.
BPC-157 crosses the blood-brain barrier; TB-500 promotes neural stem cell activation.
Dual-pathway wound healing — VEGFR2 new vessels plus cellular migration drive superior outcomes.
Safety profile
Because BPC-157 and TB-500 activate complementary pathways, their combined potency at standard research doses should be considered when designing protocols.
Pro-angiogenic potential — VEGFR2 activation warrants avoidance in active oncology models
TB-500 immunomodulatory activity — note in autoimmune research contexts
Growth hormone receptor upregulation — theoretical concern in IGF-sensitive models
Anti-fibrotic effect may alter wound healing timelines vs control groups
Molecular profile
Frequently asked questions
BPC-157 and TB-500 work through completely independent mechanisms — VEGFR2 angiogenesis and G-actin sequestering respectively. Because they do not compete for the same receptors or pathways, the full dose effect of each is maintained when combined. This produces synergistic tissue repair that neither can achieve alone.
Growth hormone receptor (GHR) density on tendon tissue increases 7-fold at Day 3 of BPC-157 treatment in animal models. This sensitizes the tissue to growth hormone signaling, dramatically amplifying the anabolic and repair response beyond what GH alone can achieve.
In standard acute toxicity studies, researchers progressively increase dosage until they find the lethal dose for 50% of subjects (LD50). For both BPC-157 and TB-500, no lethal dose was found at any tested amount. This unusually favorable safety profile reflects their endogenous origins.
Add bacteriostatic water slowly to the lyophilized powder — do not inject water directly onto the powder, allow it to run down the side of the vial. Do not shake — gently swirl until dissolved. Store reconstituted at 2-8°C for up to 30 days. Do not freeze after reconstitution.
Yes. Both BPC-157 and TB-500 are prohibited by WADA under category S0 (non-approved substances). This applies in-competition and out-of-competition. This product is for research use only.
Both compounds have been studied across tendon, muscle, bone, cardiac, neural, gastrointestinal, and skin tissue types. TB-500 has completed Phase 1 human data. BPC-157 has extensive preclinical data across all major tissue types.
References
